Printer Friendly

ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER

 ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS
 WITH DRUG FOR PROSTATE CANCER
 EATONTOWN, N.J., Feb. 19 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced earlier today that its IND submission for SOMAGARD (deslorelin) has successfully passed the FDA initial requirements and that the company will begin multicenter clinical trials for the treatment of prostate cancer. SOMAGARD is an endocrine drug which suppresses the production of testosterone by the male sex glands making the prostate cancer more amenable to treatment with other chemotherapy or surgery. In clinical studies conducted outside of the U.S., SOMAGARD has been demonstrated to be of value in the management of prostate cancer. Use of the drug in cancer patients improved both the quality of life and length of survival of the affected patients. In this connection, Roberts recently received regulatory approval for SOMAGARD for the treatment of prostate cancer in the Republic of Ireland.
 Roberts CEO and President, Robert A. Vukovich reported, "Prostate cancer is the second indication for SOMAGARD that Roberts is pursuing. The initial indication is for central precocious puberty, a children's endocrine disease." He continued, "We are pleased that the FDA has allowed Roberts to begin U.S. prostate cancer clinical trials with SOMAGARD under a new IND, and that the trials are proceeding on schedule. These studies, when completed, will form the foundation for a second SOMAGARD New Drug Application."
 Approximately 100,000 new cases of prostate cancer are diagnosed annually in the United States and about 1 out of 11 men will develop prostate cancer at some time during their lifetimes. Prostate cancer is the third most common cancer in men next to skin cancer and lung cancer. Nearly 30,000 deaths occur annually in the U.S. from prostate cancer making this tumor the third leading cause of cancer deaths in men.
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing, and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 -0- 2/19/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:


SH-OS -- NY070 -- 0589 02/19/92 16:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 19, 1992
Words:395
Previous Article:MERRILL LYNCH $425 MILLION NOTES RATED 'A+' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:LEONA ENTERPRISES REVISES DIVIDEND POLICY
Topics:


Related Articles
MATRIX PHARMACEUTICAL RECEIVES APPROVALS FOR HUMAN CLINICAL TRIALS IN CANCER
ROBERTS PHARMACEUTICAL RECEIVES IRISH APPROVAL FOR PROSTATE CANCER DRUG
/C O R R E C T I O N -- ROBERTS PHARMACEUTICALS/
Novogen Anti-Cancer Drug Enters Phase I Clinical Trials.
Barr Says Patient Recruitment for CyPat(TM) Prostate Drug Clinical Trials Underway.
Cellegy Pharmaceuticals Consultant Receives U.S. Army Grant for Prostate Cancer Research Project Using Cellegy Technology; Army Review Panel 'Highly...
Progen Expand PI-88 Clinical Development to Prostate Cancer.
ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA.
Reportlinker Adds World Cancer Therapies Market Report.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters